EVALUATION OF SAFETY, TOLERABILITY AND PHARMACOKINETIC CHARACTERISTICS OF MULTIPLE-ASCENDING DOSES OF CG400549 IN HEALTHY VOLUNTEERS

Completed

• Conditions: MRSA; 10004018

• Registration Number: NL-OMON34490
• Lead Sponsor: Crystal Genomics

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Sex: male
Age: 18-55 years, inclusive
BMI: 19-30 kg/m2
No relevant deviations at screening

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/AIDS.
In case of participation in another drug study within 60 days before the start of this study or being a blood donor (50 mL or more) within 60 days from the start of the study. In case of donating more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months preceding the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics: plasma and urine CG400549 concentrations, pharmacokinetic<br /><br>parameters<br /><br><br /><br>Safety : adverse events, vital signs, ECG-parameters, laboratory parameters,<br /><br>physical examination, </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N/A</p><br>